CLAIMS

1. Use of a topical composition comprising cannabidiol (CBD) in the preparation of a medicament for treating female sexual dysfunction induced by one or more antidepressants, previously administered to a female subject, wherein: the medicament is adapted for application to a mucosal surface of the female subject's genital (arousal) area(s); and the medicament is adapted for application in an amount and for a period of time prior to a sexual activity for ameliorating the sexual dysfunction during the sexual activity.

2. The use of claim 1, wherein said topical composition is formulated as a lotion, an ointment, a cream, a suspension, a paste, a gel, a balm, a tincture, an emulsion, or a serum.

3. The use of claim 1, wherein the genital area includes genitalia with absorptive mucosa, comprising one or more of: introitus, vulva, labia minora, clitoris and vaginal vault.

4. The use of claim 1, wherein the one or more antidepressant causing sexual dysfunction is selected from: an SSRI, an SNRI, a tricyclic antidepressant, and a tetracyclic depressant.

5. The use of claim 4, wherein:

a) the SSRI is selected from: sertraline, citalopram, fluoxetine, escitalopram, paroxetine, fluvoxamine, duloxetine, venlafaxine, and desvenlafaxine;

b) the SNRI is selected from: duloxetine, venlafaxine, desvenlafaxine, milnacipran, and levomilnacipran;

c) the tricyclic antidepressant is selected from: clomipramine, trimipramine, amitriptyline, desipramine, imipramine, lofepramine, doxepin, nortriptyline, amoxapine, and protriptyline; and/or

d) the tetracyclic antidepressant is selected from maprotiline and mirtazapine.

6. The use as in claim 1, wherein the female subject is human and has been diagnosed with one or more disorders or conditions selected from the group consisting of major depressive disorder (MDD), persistent depressive disorder or dysthymia, melancholic depression, anxiety disorder (e.g., generalized anxiety disorder (GAD) and social anxiety disorder (SAD)), attention-deficit hyperactivity disorder (ADHD), obsessive–compulsive

disorder (OCD), bulimia nervosa (bulimia), panic disorder, premenstrual dysphoric disorder, menopause-associated vasomotor symptoms, fibromyalgia, neuropathic pain, post-traumatic stress disorder (PTSD), diabetic peripheral neuropathy (DPN), and chemotherapy-induced neuropathy.

7. The use of claim 1, wherein the female sexual dysfunction is characterized by one or more of the following characteristics: difficulty achieving arousal and/or insufficient lubrication, difficulty in achieving and maintaining engorgement, and difficulty in achieving and maintaining lubrication.

8. The use of claim 1, wherein the female sexual dysfunction is characterized by one or more of the following characteristics: difficulty achieving orgasm, low orgasm intensity, or anorgasmia.

9. The use of claim 1, wherein the female sexual dysfunction is characterized to lack of sexual desire or interest.

10. The use of claim 1, wherein the female subject is premenopausal.

11. The use of claim 1, wherein the female subject is post-menopausal.

12. The use of claim 1, wherein the female subject has previously been treated with, but did not satisfactorily respond to, one or more of the following treatments: (1) change of the time the antidepressant medication is taken, (2) drug holidays, (3) decrease of the dose of the medication, (4) switching to or addition of mirtazapine, (5) switching to or addition of bupropion, (6) addition of phosphodiesterase inhibitors (e.g., vardenafil, avanafil, and udenafil), (7) topical testosterone, (8) amantadine, (9) yohimbine, (10) switching to or addition of trazodone, (11) stimulants such as methylphenidate, (12) behavioral therapy, (13) dietary supplements, e.g., saffron, and (14) acupuncture.

13. The use of claim 1, wherein the female subject is further treated with one or more of the following treatments: (1) change of the time the antidepressant medication is taken, (2) drug holidays, (3) decrease the dose of the medication, (4) switching to or addition of mirtazapine, (5) switching to or addition of bupropion, (6) addition of phosphodiesterase inhibitors (e.g., vardenafil, avanafil, and udenafil), (7) topical testosterone, (8) amantadine, (9) yohimbine, (10) switching to or addition of trazodone, (11) stimulants such as methylphenidate, (12) behavioral therapy, (13) dietary supplements, e.g., saffron, and (14) acupuncture.

14. The use of claim 1, wherein ameliorating the sexual dysfunction is exhibited by one or both of the following parameters:

i. vaginal and clitoral smooth muscle relaxation; and
ii. increased vaginal and clitoral blood flow.

15. The use of claim 1, wherein ameliorating the sexual dysfunction is exhibited by one or more of the following subjectively self-reported outcomes including:

i. “increased lubrication/wetness during sexual activity”;
ii. “reaching orgasm more often”;
iii. “greater ease or achieving orgasm”;
iv. “being more satisfied”;
v. “higher level of sexual desire”; and
vi. “reduction in pain during sexual activity”.

16. The use of claim 1, wherein the total amount of CBD comprising the topical composition is from 5 mg to 1,000 mg of CBD; 10-100 mg of CBD; or 20-40 mg of CBD.

17. The use of claim 1, wherein the period of time is 1-60 min prior to sexual activity; 5-40 min prior to sexual activity; or 15-20 min prior to sexual activity.

18. The use of claim 1, wherein the period of time is 5-30 mins prior to the sexual activity.

19. The use of claim 1, wherein the CBD is hemp-derived and/or contains less than 0.3% THC by weight.

20. The use of claim 1, wherein the topical composition is provided in a single- use container.

21. The use of claim 1, wherein the topical composition further comprises preservative(s) and is provided in a multi-use container.

22. The use of claim 1, wherein the concentration of CBD comprising the composition is from 1 mg/mL to 40 mg/mL; 5 mg/mL to 20 mg/mL; or 10 mg/mL.

23. The use of claim 1, wherein the subject is afflicted with a disorder selected from: (1) Sexual Interest/Arousal Disorder (SIAD); and (2) Female Orgasmic Disorder.

24. The use of claim 21 for a duration of 3-6 months, wherein the subject reports arousal and or orgasmic improvements as measured by FSFI, wherein the improvement in sexual interest/arousal domain is by 1-2 points, and by 1-2 points in the orgasm domain of the FSFI.

25. The use of claim 1, wherein the off-set time following the application of the CBD-containing composition is 0.5-5 hrs, preferably, 1-3 hrs, more preferably 1-2 hrs.

26. The use of claim 1, wherein the topical composition further comprises a phosphodiesterase type 5 (PDE-5) inhibitor.

27. The use of claim 26, wherein the PDE-5 inhibitor is chosen from: sildenafil, tadalafil, vardenafil, avanafil and udenafil.

28. The use of claim 1, wherein the topical composition further comprises another direct smooth muscle relaxant.

29. The use of claim 28, wherein the direct smooth muscle relaxant is chosen from: prostaglandin E1, papaverine and minoxidil.

30. The use of claim 1, wherein the topical composition further comprises: a) an alpha-blocker (e.g., phentolamine); b) flibanserin and/or c) bremelanotide.

31. The use of claim 1, wherein the medicament further comprises a PDE-5 inhibitor adapted for being administrated orally, or topically, before, concurrently, or after the the topical composition.

32. The use of claim 1, wherein the female subject was previously treated with an anti-depressant that induced sexual dysfunction and has persistent sexual dysfunction despite discontinuation of the anti-depressant therapy.